amiodarone and Disease, Pulmonary studies

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Research Excerpts

Excerpt	Relevance	Reference
" The question addressed was whether the administration of amiodarone is safe in patients undergoing lung resection either for prophylaxis or treatment of de novo postoperative atrial fibrillation (POAF)."	8.95	In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation? ( Billè, A; Harling, L; Kolokotroni, SM; Toufektzian, L, 2017)
"In the Atrial Fibrillation Follow-up Investigation of Rhythm Management study, preexisting pulmonary disease did not preclude the use of amiodarone."	7.73	Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. ( Greene, HL; Kostis, J; Olshansky, B; Rubin, A; Sami, M; Shorofsky, S; Slee, A, 2005)
"Cytological patterns of bronchoalveolar lavage (BAL) in pulmonary alveolar proteinosis (PAP) and amiodarone pulmonary toxicity (APT) are presented together with light and electron microscopy (EM)."	7.69	Cytology of bronchoalveolar lavage in some rare pulmonary disorders: pulmonary alveolar proteinosis and amiodarone pulmonary toxicity. ( Debeljak, A; Mermolja, M; Rott, T, 1994)
"Amiodarone, a cardiac antiarrhythmic agent, has been associated with the development of interstitial pulmonary fibrosis in patients receiving prolonged therapy with the drug."	7.67	Amiodarone-induced pulmonary fibrosis in hamsters. ( Cantor, JO; Cerreta, JM; Mandl, I; Osman, M; Suarez, R; Turino, GM, 1984)
"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs."	7.66	Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983)
"Diffuse alveolar hemorrhage is a rare reaction, with few case reports documented in the literature since amiodarone became widely used in the early 1980s."	5.38	A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. ( Bennett, S; Borders, CW; Claassen, SL; Mount, C, 2012)
"Amiodarone is an effective antiarrhythmic that has been used in Europe for over a decade and has been available for investigational use in North America for a shorter time."	5.27	Diffuse alveolar damage syndrome associated with amiodarone therapy. ( Henning, H; Huckell, VF; Jirik, FR; Ostrow, DV, 1983)
"Amiodarone is more effective than sotalol or beta-blockers in preventing inappropriate ICD shocks in patients with AF or CHF, but it has a significant risk of drug-related adverse effects."	5.13	Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. ( Choi, KJ; Kim, HY; Kim, J; Kim, YH; Lee, CH; Nam, GB; Park, HG; Park, KM, 2008)
"Amiodarone hydrochloride, which is used in life-threatening cardiac tachyarrhythmia, has been known to cause amiodarone induced pulmonary toxicity (AIPT) as a complication."	5.10	Technetium-99m-DTPA aerosol scintigraphy in amiodarone induced pulmonary toxicity in comparison with Ga-67 scintigraphy. ( Atasever, A; Bacakoglu, F; Burak, Z; Dirlik, A; Erinc, R; Nalbantgil, S; Ozcan, Z; Ozhan, M, 2002)
" The question addressed was whether the administration of amiodarone is safe in patients undergoing lung resection either for prophylaxis or treatment of de novo postoperative atrial fibrillation (POAF)."	4.95	In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation? ( Billè, A; Harling, L; Kolokotroni, SM; Toufektzian, L, 2017)
"Amiodarone is widely used in intensive care units for the treatment of a variety of arrhythmias."	4.80	Intravenous amiodarone in intensive care. Time for a reappraisal? ( Binning, A; Hughes, M, 2000)
"Amiodarone, an anti-ischaemic and anti-arrhythmic drug, has been the object of numerous studies and seems to be highly effective in the treatment of severe ventricular arrhythmias on dilated cardiomyopathies, as well as of hypertrophic or ischaemic heart diseases."	4.78	[Does amiodarone have a benefit effect on mortality?]. ( Kahn, JC; Pathé, M, 1991)
"Of the side effects that complicate amiodarone therapy, pulmonary fibrosis is potentially the most serious."	4.76	Amiodarone pulmonary toxicity. ( Mostow, N; Rakita, L; Sobol, SM; Vrobel, T, 1983)
"Amiodarone is one of the more frequently used drugs in the treatment of supraventricular and ventricular arrhythmias."	4.02	Amiodarone induced pulmonary toxicity. ( Brázdil, V; Doubková, M; Hetmer, M; Hudec, M; Kala, P; Poloczek, M; Vysočanová, P, 2021)
" Patient had atrial fibrillation on 3rd post-operative day requiring loading dose of amiodarone followed by maintenance dose to control the arrhythmia."	3.77	Ultra-short course of low-dose amiodarone-induced post-operative fatal pulmonary toxicity. ( Nair, SG; Patel, V; Viswam, D, 2011)
"In the Atrial Fibrillation Follow-up Investigation of Rhythm Management study, preexisting pulmonary disease did not preclude the use of amiodarone."	3.73	Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. ( Greene, HL; Kostis, J; Olshansky, B; Rubin, A; Sami, M; Shorofsky, S; Slee, A, 2005)
"Associated with amiodarone (AM) therapy is pneumonitis, which may progress to life-threatening pulmonary fibrosis."	3.69	Investigation of the role of oxidative stress in amiodarone-induced pulmonary toxicity in the hamster. ( Brien, JF; Leeder, RG; Massey, TE, 1994)
"Cytological patterns of bronchoalveolar lavage (BAL) in pulmonary alveolar proteinosis (PAP) and amiodarone pulmonary toxicity (APT) are presented together with light and electron microscopy (EM)."	3.69	Cytology of bronchoalveolar lavage in some rare pulmonary disorders: pulmonary alveolar proteinosis and amiodarone pulmonary toxicity. ( Debeljak, A; Mermolja, M; Rott, T, 1994)
"Intravenous amiodarone is an effective treatment for supraventricular and ventricular tachyarrhythmias."	3.69	Acute pulmonary toxicity in an infant from intravenous amiodarone. ( Daniels, CJ; Franklin, WH; Hammond, S; Schutte, DA, 1997)
"Amiodarone, a cardiac antiarrhythmic agent, has been associated with the development of interstitial pulmonary fibrosis in patients receiving prolonged therapy with the drug."	3.67	Amiodarone-induced pulmonary fibrosis in hamsters. ( Cantor, JO; Cerreta, JM; Mandl, I; Osman, M; Suarez, R; Turino, GM, 1984)
"Amiodarone is an effective agent in the treatment of life-threatening ventricular arrhythmias."	3.67	Amiodarone-induced pulmonary mass. ( Faber, LP; Piccione, W; Rosenberg, MS, 1989)
"Amiodarone hydrochloride, used for prophylaxis of recurrent ventricular tachyarrhythmias that are resistant to other agents, may cause toxic pulmonary reactions associated with abnormal chest radiographs."	3.66	Lung disease caused by amiodarone, a new antiarrythmic agent. ( Epstein, DM; Gefter, WB; Miller, WT; Pietra, GG, 1983)
"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs."	3.66	Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983)
" Group A contained patients demonstrating amiodarone lung toxicity diagnosed by chest X-ray, KL-6 or D(LCO) (n=6), whereas group B included patients treated without any adverse effects (n=20)."	2.74	Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance. ( Harada, M; Hiramatsu, S; Kuruma, T; Maruyama, T; Odashiro, K; Yasuda, S; Yasuda, Y, 2009)
" Amiodarone possesses a significant adverse reaction profile."	2.72	Acute Amiodarone Pulmonary Toxicity. ( Feduska, ET; Goldhammer, JE; Thoma, BN; Torjman, MC, 2021)
"High-resolution computed tomography used in prone positions as well as a supine position could be an effective technique for reducing false-positive results in detection of APT and preventing the clinically serious pulmonary adverse effects by amiodanone."	2.71	Detection of amiodarone-induced pulmonary toxicity in supine and prone positions: high-resolution computed tomography study. ( Kamishima, T; Miyasaka, K; Nambu, T; Oyama, N; Tsutsui, H; Yokoshiki, H, 2005)
" However, adverse effects, especially potentially fatal and non-reversible acute and chronic pulmonary toxicity, continue to be observed."	2.46	Amiodarone: review of pulmonary effects and toxicity. ( Kolilekas, L; Manali, ED; Markoulaki, D; Papiris, SA; Triantafillidou, C, 2010)
" Here, we discuss safety issues relating to the long-term use of oral amiodarone in adults."	2.42	Using oral amiodarone safely. ( , 2003)
" It is a relatively rare adverse effect of amiodarone and is easily missed by any physician who is suddenly confronted with nonspecific pulmonary complaints during amiodarone treatment."	2.40	Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. ( Boersma, WG; Crijns, HJ; Jessurun, GA, 1998)
" Although several agents have ocular effects, amiodarone is the most widely recognized for producing adverse effects in the eyes."	2.40	Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. ( Pollak, PT, 1999)
"The Authors discuss a case of amiodarone pulmonary toxicity, with simultaneous alveolar and interstitial infiltrates, in a female patient 75 years old, who took the drug for 6 months at a low dosage (200 mg/daily for 5 days a week)."	2.40	[Amiodarone pulmonary toxicity]. ( De Angelis, G; Gidaro, M; Mazzei, L; Propati, A; Sciotto, V; Sposato, B, 1999)
"Amiodarone therapy for certain life-threatening cardiac arrhythmias is associated with numerous side and adverse effects, of which pulmonary toxicity is one of the most serious adverse reactions."	2.39	[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?]. ( Aldershvile, J; Ulrik, CS, 1996)
"Although amiodarone is a highly efficacious antidysrhythmic agent, the drug produces numerous adverse effects."	2.39	Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. ( Brien, JF; Leeder, RG; Massey, TE; Rafeiro, E, 1995)
"Reports of drug-induced pulmonary disease from other countries are also reviewed."	2.38	Drug-induced pulmonary disease. ( Bryant, DH, 1992)
" Although the pathologic findings of amiodarone lung can be distinctive, the histologic demonstration of foam cells and ultrastructural lamellar inclusions alone does not distinguish toxic from nontoxic patients receiving amiodarone."	2.38	Clinical aspects of amiodarone pulmonary toxicity. ( Kennedy, JI, 1990)
" Likewise, the mechanism of amiodarone pulmonary toxicity suggests that at least two different pathways of toxicity exist: (1) an indirect mechanism characterized by influx of inflammatory or immune effector cells to the lung and (2) a direct toxic mechanism that results in lung parenchymal cell injury and a subsequent fibrotic response."	2.38	Mechanisms of amiodarone pulmonary toxicity. ( Martin, WJ, 1990)
" Amiodarone has a reduced clearance rate, large volume of distribution, low bioavailability and a long half-life that may last 2 months in patients receiving short-term therapy."	2.37	Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. ( Heger, JJ; Prystowsky, EN; Zipes, DP, 1984)
" Durations of treatment, daily doses and total dosage were extremely varied."	2.37	[The amiodarone lung]. ( Akoun, G; Mayaud, C; Milleron, B, 1984)
" A role for the direct toxicity of the drug is likely because (a) toxicity in part is related to dosage and duration of therapy, (b) many patients with amiodarone pulmonary toxicity have no evidence of an inflammatory or immune response in the lung, (c) in vitro studies indicate that amiodarone can be directly toxic to cultured lung cells or perfused isolated lung tissue, and (d) recent studies suggest plausible biochemical mechanisms that may explain in part the mechanism(s) of direct toxicity of the drug."	2.37	Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). ( Martin, WJ; Rosenow, EC, 1988)
" Amiodarone pulmonary toxicity is a potentially fatal adverse effect associated with amiodarone use."	1.72	A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. ( Chan, JWM; Ho, JCM; Kwok, WC; Ma, TF; Pang, HH, 2022)
" Despite the steady decrease of AIPT with reduced dose, it is vital for the treating clinicians to monitor regularly for adverse effects and review the need for long-term use to prevent complications."	1.62	Amiodarone lung: under recognised but not forgotten. ( Baron, E; Dwarakanath, A; Elfaki, H; Jayawardena, M; Mok, WK; Reall, G; Thirumaran, M, 2021)
"We present a 61-year-old patient with persistent atrial fibrillation who, after a one-month treatment with oral amiodarone at a low dose impregnation of 400 mg/day, develops acute pulmonary toxicity, with radiographic and tomographic resolution after antiarrhythmic suspension and steroid treatment."	1.56	[Acute amiodarone pulmonary toxicity with low impregnation dose: case report]. ( Cabrera-Rego, JO; Luzurriaga Navas, JD; Yanes Quintana, AA, 2020)
" One of the most devastating adverse reactions to this drug is pulmonary toxicity, which can present in a myriad of different ways."	1.46	Amiodarone-induced pulmonary toxicity. ( Colby, R; Geyer, H, 2017)
"Amiodarone-induced pulmonary toxicity (APT) is a serious adverse event that can lead to death."	1.40	Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. ( Cormier, B; Diot, P; Favelle, O; Guilleminault, L; Guillon, A; Jonville-Béra, AP; Mankikian, J; Marchand-Adam, S; Perrotin, D, 2014)
"Diffuse alveolar hemorrhage is a rare reaction, with few case reports documented in the literature since amiodarone became widely used in the early 1980s."	1.38	A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. ( Bennett, S; Borders, CW; Claassen, SL; Mount, C, 2012)
"Phospholipidosis (PLD) is a topic of concern in drug development because it may be associated with toxicological consequences."	1.37	Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. ( Atienzar, FA; Cossu-Leguille, C; Depelchin, O; Dhalluin, S; Gerets, HH; Hanon, E; Tilmant, K; Vasseur, P, 2011)
"Amiodarone (AMD) is a strong antiarrhythmic drug but has severe side effects such as pulmonary toxicity."	1.36	Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. ( Banba, K; Fuke, S; Kusano, KF; Morita, H; Murakami, M; Nagase, S; Nakamura, K; Nikaido, A; Nishii, N; Ohe, T; Sakuragi, S; Tada, T, 2010)
" Its utility is, however, limited by adverse side effects."	1.35	Reduction of amiodarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. ( Bailey, B; Byrd, RP; Halawa, A; Kosseifi, SG; Micklewright, M; Roy, TM, 2009)
"Amiodarone is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported."	1.35	Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings. ( Katayama, T; Kimura, T; Kuramochi, S; Okada, Y; Ueda, Y; Yamada, T; Yoshikawa, T, 2008)
"Amiodarone-induced pulmonary toxicity (APT) is the most serious side-effect of amiodarone, and its detection and prevention are extremely important."	1.34	Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. ( Hagiwara, N; Kasanuki, H; Matsuda, N; Shiga, T; Yamada, Y, 2007)
" Thus, clinicians should prescribe the lowest dosage possible in the elderly and have a low threshold to discontinue the amiodarone for anyone with unexplained fatigue, dyspnea, cough, or weight loss."	1.33	An unintended consequence: fatal amiodarone pulmonary toxicity in an older woman. ( Charette, S; Smith, MI; Wang, T, 2006)
"Amiodarone is a highly effective antiarrhythmic drug, albeit notorious for its serious pulmonary toxicity."	1.33	Amiodarone-induced acute lung toxicity in an ICU setting. ( Galiatsou, E; Karahaliou, A; Kitsakos, A; Metafratzi, Z; Nakos, G; Skroubis, G; Skroubis, T, 2005)
"Amiodarone is an effective antiarrhytmic drug and it is used to treat supraventricular or ventricular rhythm disturbances."	1.32	[Late postoperative amiodarone pulmonary toxicity]. ( Alonso-Fernández, A; Alvarez-Sala, R; Mediano, O; Moreno, I; Torres, I, 2003)
"Amiodarone (AD) is a very effective anti-arrhythmic drug, but its use is often associated with serious pulmonary complications such as pneumonitis and interstitial pulmonary disease."	1.31	Use of technetium-99m HMPAO scintigraphy for the detection of amiodarone lung toxicity in a rabbit model. ( Bekis, R; Capa Kaya, G; Durak, H; Ertay, T; Gure, A; Kargi, A; Kirimca, F, 2001)
"Amiodarone pulmonary toxicity is a serious adverse effect that can be fatal."	1.31	Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan. ( Narula, D; Siniakowicz, RM; Steinberg, JS; Suster, B, 2001)
"To understand the bioavailability and mechanistic pathways of cytoprotection by IH636 grape seed proanthocyanidin extract (GSPE, commercially known as ActiVin) a series of in vitro and in vivo studies were conducted."	1.31	Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract. ( Bagchi, D; Bagchi, M; Preuss, HG; Ray, SD; Stohs, SJ, 2002)
" The patient had been treated with amiodarone for four years in daily dose 200 mg/day without any adverse effects until the daily dose was doubled."	1.30	[Pulmonary adverse effect after amiodarone treatment--case report]. ( Kamiński, J; Kozielski, J; Oklek, K; Ziora, D, 1999)
"Amiodarone-induced pulmonary toxicity (AIPT) is one of the most serious adverse effects of amiodarone therapy and can be fatal."	1.30	Amiodarone-induced pulmonary toxicity. ( Gin, K; Kanji, Z; Sunderji, R, 1999)
"Noncardiovascular adverse effects associated with amiodarone result in substantial morbidity."	1.29	Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. ( Follin, SL; Ordelova, A; Tisdale, JE; Webb, CR, 1995)
"Exposure to the toxic mineral dust silica has been shown to produce an acute inflammatory response in the lungs of both humans and laboratory animals."	1.29	Acute silica toxicity: attenuation by amiodarone-induced pulmonary phospholipidosis. ( Antonini, JM; McCloud, CM; Reasor, MJ, 1994)
"Amiodarone (AM) is an effective antidysrhythmic agent, restricted in use by the development of adverse effects, including potentially fatal AM-induced pulmonary toxicity (AIPT)."	1.29	Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. ( Brien, JF; Leeder, RG; Mandin, CC; Massey, TE; Rafeiro, E, 1996)
" However, it has a wide profile of adverse effects involving a number of organ systems."	1.28	Amiodarone pulmonary toxicity--three unusual manifestations. ( Firouz-Abadi, A; McNeil, KD; Oliver, W; Zimmerman, PV, 1992)
"Amiodarone (A) is a widely-used antiarrhythmic drug."	1.28	Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. ( Escamilla, R; Migueres, J; Nicolet-Chatelain, G; Prevost, MC, 1991)
"In amiodarone-treated patients, the major findings were as follows: a 50% incidence of hepatic dysfunction with a tenfold increase in concentrations of serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase; a 25% incidence of pulmonary dysfunction necessitating a fourfold increase in the number of days of ventilator support; and a 19% incidence of low cardiac output syndrome with two deaths."	1.28	Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy. ( Clark, RE; Kupferschmid, JP; Leon, MB; McIntosh, CL; Rosengart, TK, 1989)
"Mild pleuroparenchymal fibrosis associated with amiodarone pulmonary toxicity is reported in a 63-year-old white man; partial radiographic resolution and complete symptomatic resolution with decreasing the daily dosage to 200 mg permitted continued anti arrhythmic therapy."	1.27	Pulmonary toxicity of amiodarone. ( Gallastegui, J; Leech, JA; Swiryn, S, 1984)
"The relationships between size of loading dose and drug concentration, size of maintenance dose and drug concentration, and pulmonary and cutaneous adverse side effects and drug dosage were examined in patients given amiodarone."	1.27	Relationships between amiodarone dosage, drug concentrations, and adverse side effects. ( Heger, JJ; Prystowsky, EN; Zipes, DP, 1983)
"Amiodarone is an effective antiarrhythmic that has been used in Europe for over a decade and has been available for investigational use in North America for a shorter time."	1.27	Diffuse alveolar damage syndrome associated with amiodarone therapy. ( Henning, H; Huckell, VF; Jirik, FR; Ostrow, DV, 1983)
"Amiodarone may cause pulmonary toxicity mimicking metastatic lung disease."	1.27	Amiodarone-induced pulmonary toxicity mimicking metastatic lung disease. ( Honeybourne, D; Patel, P; Watson, RD, 1987)
"We have studied 15 patients with amiodarone pulmonary toxicity and compared them with five amiodarone patients without evidence of toxic effect."	1.27	Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations. ( Fulmer, JD; Kennedy, JI; Myers, JL; Plumb, VJ, 1987)
"Amiodarone is an investigational antiarrhythmic agent known to cause pulmonary toxicity."	1.27	Amiodarone pulmonary toxicity: early changes in pulmonary function tests during amiodarone rechallenge. ( Reid, PR; Veltri, EP, 1985)

Timeframe	Studies, this research(%)	All Research%
pre-1990	63 (29.72)	18.7374
1990's	65 (30.66)	18.2507
2000's	55 (25.94)	29.6817
2010's	20 (9.43)	24.3611
2020's	9 (4.25)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery[NCT00127712]	Phase 4	130 participants (Actual)	Interventional	2004-09-30	Completed
Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150]		80 participants (Actual)	Observational	2007-01-31	Completed
[NCT00000556]	Phase 3	0 participants	Interventional	1995-03-31	Completed
Telemedicine Enabling Patients in Self-care Behaviors[NCT04297735]		60 participants (Actual)	Interventional	2020-02-26	Completed
aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980]		500 participants (Anticipated)	Observational	2015-01-01	Recruiting
[NCT00000464]	Phase 3	0 participants	Interventional	1987-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Number)
Amiodarone	9
Control	22

Intervention	participants (Number)
Amiodarone	9
Control	21

Intervention	Days (Median)
Amiodarone	7
Control	8

amiodarone and Disease, Pulmonary

Research Excerpts

Research

Studies (212)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Incidence of Atrial Fibrillation Lasting Longer Than 30 Seconds

Incidence of Atrial Fibrillation Requiring Treatment

Length of Hospital Stay

Length of Intensive Care Unit Stay

Reviews

Trials

Other Studies

Authors	Studies
Kwok, WC	1
Ma, TF	1
Chan, JWM	1
Pang, HH	1
Ho, JCM	1
Hudec, M	1
Vysočanová, P	1
Brázdil, V	1
Poloczek, M	1
Hetmer, M	1
Doubková, M	1
Kala, P	1
Papanikolaou, IC	1
Makou, I	1
Markatis, E	1
Cabrera-Rego, JO	1
Luzurriaga Navas, JD	1
Yanes Quintana, AA	1
Soker, T	1
Yang, M	1
Gilkeson, RC	2
Ansari-Gilani, K	2
Feduska, ET	1
Thoma, BN	1
Torjman, MC	1
Goldhammer, JE	1
Rôlo Silvestre, CM	1
Nunes, A	1
Cordeiro, RJ	1
Eusébio, JP	1
Vilaça, MT	1
Falcão, T	1
Domingos, AC	1
Baron, E	1
Mok, WK	1
Jayawardena, M	1
Reall, G	1
Elfaki, H	1
Thirumaran, M	1
Dwarakanath, A	1
Fegley, MW	1
Cardi, A	1
Augoustides, JG	1
Horak, J	1
Gutsche, JT	1
Nanda, S	1
Kornfield, ZN	1
Saluja, A	1
Sanders, J	1
Marchant, BE	1
Fernando, RJ	1
Kolokotroni, SM	1
Toufektzian, L	1
Harling, L	1
Billè, A	1
Colby, R	1
Geyer, H	1
Keng, LT	1
Liao, MT	1
Oh, E	1
Siddiqui, N	2
Worringer, E	1
Schroeder, K	1
Markowiak, S	1
Alrehaili, M	1
Safi, F	1
Hinch, BT	1
Assaly, R	2
Ul Rehman, S	1
Khan, NS	1
Sobia, R	1
Mankikian, J	1
Favelle, O	1
Guillon, A	1
Guilleminault, L	1
Cormier, B	1
Jonville-Béra, AP	1
Perrotin, D	1
Diot, P	1
Marchand-Adam, S	1
Hsiao, EM	1
Rajiah, P	1
Kuruma, T	1
Maruyama, T	1
Hiramatsu, S	1
Yasuda, Y	1
Yasuda, S	1
Odashiro, K	1
Harada, M	1
Ruangchira-Urai, R	1
Colby, TV	1
Klein, J	1
Nielsen, GP	1
Kradin, RL	1
Mark, EJ	1
Dharmarajan, TS	1
Shah, AB	1
Dharmarajan, L	1
Kimura, T	1
Kuramochi, S	1
Katayama, T	1
Yoshikawa, T	1
Yamada, T	1
Ueda, Y	1
Okada, Y	1
Jamshidzadeh, A	1
Baghban, M	1
Azarpira, N	1
Mohammadi Bardbori, A	1
Niknahad, H	1
Nikaido, A	1
Tada, T	1
Nakamura, K	1
Murakami, M	1
Banba, K	1
Nishii, N	1
Fuke, S	1
Nagase, S	1
Sakuragi, S	1
Morita, H	1
Ohe, T	1
Kusano, KF	1
Tisdale, JE	2
Wroblewski, HA	1
Wall, DS	1
Rieger, KM	1
Hammoud, ZT	1
Young, JV	1
Kesler, KA	1
Bischoff, A	1
Kosseifi, SG	1
Halawa, A	2
Bailey, B	1
Micklewright, M	1
Roy, TM	2
Byrd, RP	2
Papiris, SA	2
Triantafillidou, C	1
Kolilekas, L	1
Markoulaki, D	1
Manali, ED	1
Kudelko, KT	1
Nadeau, K	1
Leung, AN	1
Liu, J	1
Haddad, F	1
Zamanian, RT	1
De Jesus Perez, V	1
Schreiber, J	1
Tilmant, K	1
Gerets, HH	1
Dhalluin, S	1
Hanon, E	1
Depelchin, O	1
Cossu-Leguille, C	1
Vasseur, P	1
Atienzar, FA	1
Liyanage, UA	1
Rajapakse, T	1
Somaratne, SC	1
Gunaratne, PS	1
Viswam, D	1
Nair, SG	1
Patel, V	1
Borders, CW	1
Bennett, S	1
Mount, C	1
Claassen, SL	1
Siu, CW	1
Wong, MP	1
Ho, CM	1
Lam, CL	1
Tse, HF	1
Goldschlager, N	2
Hudzik, B	1
Polonski, L	1
Blasco, LM	1
Duello, KM	1
Louh, IK	1
Burger, CD	1
Dirlik, A	1
Erinc, R	1
Ozcan, Z	1
Atasever, A	1
Bacakoglu, F	1
Nalbantgil, S	1
Ozhan, M	1
Burak, Z	1
García de Luca, MD	1
Jurado Gámez, B	1
de Toro Torres, E	1
Izquierdo Palomares, L	1
Trujillo-Santos, AJ	1
García López, P	1
Bagchi, D	2
Ray, SD	2
Bagchi, M	1
Preuss, HG	1
Stohs, SJ	1
Healy, EC	1
Taylor, MD	1
Antonini, JM	2
Roberts, JR	1
Leonard, SS	1
Shi, X	1
Gannett, PM	1
Hubbs, AF	1
Reasor, MJ	2
Alonso-Fernández, A	1
Alvarez-Sala, R	1
Mediano, O	1
Torres, I	1
Moreno, I	1
Brinker, A	1
Johnston, M	1
Camus, P	2
Bonniaud, P	1
Fanton, A	1
Camus, C	1
Baudaun, N	1
Foucher, P	2
Olshansky, B	3
Sami, M	1
Rubin, A	1
Kostis, J	1
Shorofsky, S	1
Slee, A	1
Greene, HL	2
Skroubis, G	1
Skroubis, T	1
Galiatsou, E	1
Metafratzi, Z	1
Karahaliou, A	1
Kitsakos, A	1
Nakos, G	1
Oyama, N	2
Yokoshiki, H	1
Kamishima, T	1
Nambu, T	1
Tsutsui, H	1
Miyasaka, K	1
Inampudi, P	1
Gross, BH	1
Tankanow, LB	1
Bernal Morell, E	1
Hernández Madrid, A	1
Marín Marín, I	1
Rodríguez Pena, R	1
González Gordaliza, MC	1
Moro, C	1
Durmuş-Altun, G	1
Altun, A	1
Aktas, RG	1
Salihoglu, YS	1
Yigitbasi, NO	1
Desai, KR	1
Ho, AM	1
Karmakar, MK	1
Fung, RC	1
Chan, WK	1
Chu, CM	1
Yue, CS	1
Muccino, KA	1
Venkatesan, T	1
Ninan, S	1
Singh, S	1
Iskandar, SB	1
Abi-Saleh, B	1
Keith, RL	1
Wang, T	1
Charette, S	1
Smith, MI	1
Kaya, GK	1
Ozdogan, O	1
Guneri, S	1
Tamc, B	1
Durak, H	2
Nakayama, S	1
Mukae, H	1
Ishimatsu, Y	1
Sugiyama, K	1
Ide, M	1
Ishimoto, H	1
Hisatomi, K	1
Ishii, H	1
Abel, K	1
Ozono, Y	1
Kohno, S	1
Gupta, S	1
Mahipal, A	1
Jarand, J	1
Lee, A	1
Leigh, R	1
Epstein, AE	1
Naccarelli, GV	1
Singh, B	1
Collard, HR	1
Murphy, E	1
Yamada, Y	1
Shiga, T	1
Matsuda, N	1
Hagiwara, N	1
Kasanuki, H	1
Argyriou, M	1
Hountis, P	1
Antonopoulos, N	1
Mathioudaki, M	1
Lee, CH	1
Nam, GB	1
Park, HG	1
Kim, HY	1
Park, KM	1
Kim, J	1
Choi, KJ	1
Kim, YH	1
Colgan, T	1
Simon, GT	1
Kay, JM	1
Pugsley, SO	1
Eydt, J	1
Pannier, R	1
Brambilla, C	2
Chavez, L	1
Piot, M	1
Rigaud, D	1
Paramelle, B	2
Rakita, L	1
Sobol, SM	1
Mostow, N	1
Vrobel, T	1
Zipes, DP	3
Prystowsky, EN	2
Heger, JJ	3
Akoun, G	1
Milleron, B	1
Mayaud, C	1
McKenna, WJ	2
Rowland, E	2
Krikler, DM	2
Kudenchuk, PJ	1
Pierson, DJ	1
Graham, EL	1
Sears, GK	1
Trobaugh, GB	1
Farmakis, M	1
Litos, G	1
Melissinos, C	1
Vic, P	2
Harris, L	1
Morady, F	1
Sauve, MJ	1
Malone, P	1
Shen, EN	1
Schwartz, AB	1
Bhandari, A	1
Keung, E	1
Sung, RJ	1
Scheinman, MM	1
Leech, JA	1
Gallastegui, J	1
Swiryn, S	1
Criée, CP	1
Wilhelms, E	1
Kneba, M	1
Kreuzer, H	1
Cantor, JO	1
Osman, M	1
Cerreta, JM	1
Suarez, R	1
Mandl, I	1
Turino, GM	1
Wright, AJ	2
Brackenridge, RG	1
Gefter, WB	1
Epstein, DM	1
Pietra, GG	1
Miller, WT	1
Jirik, FR	1
Henning, H	1
Huckell, VF	1
Ostrow, DV	1
Dake, MD	3
Golden, JA	2
Marchlinski, FE	1
Gansler, TS	1
Waxman, HL	1
Josephson, ME	1
Rosenow, EC	3
Limper, AH	1
Donado Uña, JR	1
López Encuentra, A	1
Echave-Sustaeta, JM	1
Follin, SL	1
Ordelova, A	1
Webb, CR	1
McCloud, CM	1
Leeder, RG	3
Brien, JF	4
Massey, TE	4
Paoletti, V	1
Galeotta, G	1
Mammarella, A	1
Musca, A	1
Maniati, MA	1
Manoussakis, MN	1
Constantopoulos, SH	1
Chai, JL	1
Patz, EF	1
Mermolja, M	1
Rott, T	1
Debeljak, A	1
Hopper, KD	1
Potok, PS	1
Delany, SG	1
Taylor, DR	1
Restieaux, N	1
Doyle, TC	1
Morrow, B	1
Shorten, GD	1
Sylvester, W	1
Gilbert, TB	1
Kent, JL	1
Foster, AH	1
Gold, MR	1
Fraire, AE	1
Guntupalli, KK	1
Greenberg, SD	1
Cartwright, J	1
Chasen, MH	1
Lapinsky, SE	1
Mullen, JB	1
Balter, MS	1
Ulrik, CS	1
Aldershvile, J	1
Israël-Biet, D	1
Cadranel, J	1
Wilson, BD	2
Lippmann, ML	2
Rafeiro, E	2
Mandin, CC	1
Jessurun, GA	2
Crijns, HJ	2
Mendonça, C	1
Pereira, A	1
Longo, S	1
Lousada, N	1
Loureiro, A	1
Correia, JF	1
Incalzi, RA	1
Gemma, A	1
Carbonin, PU	1
Leonard, A	1
Corris, P	1
Parums, D	1
Donaldson, L	1
Grant, IS	1
Naysmith, MR	1
Thomas, JS	1
Daniels, CJ	1
Schutte, DA	1
Hammond, S	1
Franklin, WH	1
Cole, TJ	1
Proto, AV	1
Verswijvel, G	1
Franssens, Y	1
Deraemaeker, L	1
Leyssens, G	1
Govaerts, E	1
Theunissen, P	1
Boersma, WG	1
Birmingham, WP	1
Bedrossian, CW	1
Warren, CJ	1
Ohar, J	1
Bhan, R	1
Iskander, S	1
Raible, DG	1
Brozena, SC	1
Gaitanaru, DM	1
Ayala, G	1
Iskandrian, AE	1
Devine, PL	1
Siebert, WJ	1
Morton, SL	1
Scells, B	1
Quin, RJ	1
Heddle, WF	1
Zimmerman, PV	2
Donohoe, PJ	1
Rabe, J	1
Kulinna, W	1
Lehmann, KJ	1
Georgi, M	1
Gorbatovskaia, IaA	1
Filimonov, SN	1
Gaĭdukova, NA	1
Pak, TI	1
Klimina, NV	1
Pollak, PT	2
Ziora, D	1
Kamiński, J	1
Kozielski, J	1
Oklek, K	1
Mattila, MJ	1
Kanji, Z	2
Sunderji, R	2
Gin, K	2
Mazzei, L	1
Sposato, B	1
Propati, A	1
Gidaro, M	1
Sciotto, V	1
De Angelis, G	1
Carrión Valero, F	1
Marín Pardo, J	1
Kagawa, FT	1
Kirsch, CM	1
Jensen, WA	1
Wehner, JH	1
Newton, JL	1
Cox, G	1
Johnson, J	1
Kinnear, WJ	1
Johnston, ID	1
Hughes, M	1
Binning, A	1
Capa Kaya, G	1
Bekis, R	1
Kirimca, F	1
Ertay, T	1
Kargi, A	1
Gure, A	1
Mason, JW	1
Siniakowicz, RM	2
Narula, D	1
Suster, B	1
Steinberg, JS	2
Patel, D	1
Wong, V	1
Bhagat, R	1
Sporn, TA	1
Long, GD	1
Folz, RJ	1
Bolt, MW	1
Card, JW	1
Racz, WJ	1
Kaushik, S	1
Hussain, A	1
Clarke, P	1
Lazar, HL	1
Scharf, C	1
Oechslin, EN	1
Salomon, F	1
Kiowski, W	1
Lardinois, D	1
Handschin, A	1
Weder, W	1
Trzpuc, TD	1
Shidham, VB	1
Rao, RN	1
Chabot, F	1
Aymard, B	1
Lesur, O	1
Kheir, A	1
Moreau, L	1
Cornette, A	1
Gerard, H	1
Delorme, N	1
Polu, JM	1
Bryant, DH	1
Piazza, I	1
Bizzaro, N	1
Retz, JL	1
Martin, WJ	5
McNeil, KD	1
Firouz-Abadi, A	1
Oliver, W	1
Smith, GJ	1
Kuhlman, JE	2
Pathé, M	1
Kahn, JC	1
Stover, DE	1
Rubin, DA	1
McAllister, A	1
Sorbera, C	1
Kay, RH	1
Nicolet-Chatelain, G	1
Prevost, MC	1
Escamilla, R	1
Migueres, J	1
Billmann, P	1
Fleischmann, D	1
Baumeister, L	1
Rogers, JG	1
Windle, JR	1
McManus, BM	1
Easley, AR	1
Kennedy, JI	2
Vítovec, J	1
Bulka, J	1
Kolek, V	1
Dusek, J	1
Dusková, M	1
Václavík, A	1
Vomácka, Z	1
Sharma, AD	1
Carruthers, SG	1
Dusman, RE	1
Stanton, MS	1
Miles, WM	1
Klein, LS	1
Fineberg, NS	1
Teigen, C	1
Ren, H	1
Hruban, RH	1
Hutchins, GM	1
Fishman, EK	1
Hurban, RH	1
White, JP	1
Ward, MJ	1
Brett, W	1
Cooper, JA	1
Zitnik, RJ	1
Matthay, RA	1
Perrichon, M	1
Coudert, B	2
Bailly, F	1
Solary, E	1
Jeannin, L	1
Reĭngardene, DI	2
Keleras, EIu	2
Piccione, W	1
Faber, LP	1
Rosenberg, MS	1
Kupferschmid, JP	1
Rosengart, TK	1
McIntosh, CL	1
Leon, MB	1
Clark, RE	1
Willems, AR	1
Schöttelndreiër, MA	1
Kerin, NZ	1
Rubenfire, M	1
Madison, JM	1
Montgomery, CK	1
Shellito, JE	1
Hinchcliffe, WA	1
Winkler, ML	1
Bainton, DF	1
Heath, MF	1
Costa-Jussà, FR	1
Jacobs, JM	1
Jacobson, W	1
Costa, C	1
Visalli, N	1
Natoli, A	1
Fossati, C	1
Liu, FL	1
Cohen, RD	1
Downar, E	1
Butany, JW	1
Edelson, JD	1
Rebuck, AS	1
Arnon, R	1
Raz, I	1
Chajek-Shaul, T	1
Berkman, N	1
Fields, S	1
Bar-On, H	1
Zhu, YY	1
Botvinick, E	1
Dae, M	1
Golden, J	1
Hattner, R	2
Scheinman, M	1
Joshi, UM	1
Kodavanti, PR	1
Dwyer, TM	1
Mehendale, HM	1
Magro, SA	1
Lawrence, EC	1
Wheeler, SH	1
Krafchek, J	1
Lin, HT	1
Wyndham, CR	1
Horowitz, LN	1
Manzano Espinosa, L	1
Yebra Bango, M	1
Merino Morales, F	1
Lladós Comenge, G	1
de Diego Marín, FJ	1
Durántez Martínez, A	1
Moinuddin, M	1
Rockett, J	1
Crass, JR	1
Day, DL	1
Letourneau, JG	1
Goldberg, ME	1
Ruiz Manzano, J	1
Morera Prat, J	1
Michel, FB	1
Godard, P	1
Aubas, P	1
Disertori, M	1
Inama, G	1
Patel, P	1
Honeybourne, D	1
Watson, RD	1
Khoury, Z	1
Ben-Dov, I	1
Mogle, P	1
Shalev, O	1
Chapman, KR	1
Adams, PC	1
Gibson, GJ	1
Morley, AR	1
Corris, PA	1
Reid, DS	1
Campbell, RW	1
Dean, PJ	1
Groshart, KD	1
Porterfield, JG	1
Iansmith, DH	1
Golden, EB	1
Myers, JL	1
Plumb, VJ	1
Fulmer, JD	1
Dunn, M	1
Dimitriou, R	1
Mallion, JM	1
Perdrix, A	1
Barnoud, D	1
De Gaudemaris, R	1
Gibb, P	1
Melendez, LJ	1
Weingarten, JS	1
Warnock, ML	1
Standertskjöld-Nordenstam, CG	1
Wandtke, JC	1
Hood, WB	1
Zugibe, FT	1
Butler, L	1
Lieberman, D	1
Shachor, Y	1
Veltri, EP	1
Reid, PR	1

Article	Year
Acute Amiodarone Pulmonary Toxicity. Journal of cardiothoracic and vascular anesthesia, 2021, Volume: 35, Issue:5 Topics: Amiodarone; Anti-Arrhythmia Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Di	2021
In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation? Interactive cardiovascular and thoracic surgery, 2017, 05-01, Volume: 24, Issue:5 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Lung Diseases; Pneumonectomy;	2017
Amiodarone: review of pulmonary effects and toxicity. Drug safety, 2010, Jul-01, Volume: 33, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Anti-Arrhythmia Agents; Drug-Related Side Effec	2010
[Drug-induced lung diseases]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:13 Topics: Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Bronchial Diseases; Diagnosis, Differenti	2011
Using oral amiodarone safely. Drug and therapeutics bulletin, 2003, Volume: 41, Issue:2 Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Eruptions; Drug	2003
Drug-induced and iatrogenic infiltrative lung disease. Clinics in chest medicine, 2004, Volume: 25, Issue:3 Topics: Amiodarone; Anti-Arrhythmia Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Iatroge	2004
Amiodarone pulmonary toxicity. American heart journal, 1983, Volume: 106, Issue:4 Pt 2 Topics: Adrenal Cortex Hormones; Adult; Aged; Amiodarone; Benzofurans; Dose-Response Relationship, Drug; Fem	1983
Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. Journal of the American College of Cardiology, 1984, Volume: 3, Issue:4 Topics: Administration, Oral; Amiodarone; Animals; Arrhythmias, Cardiac; Atrioventricular Node; Benzofurans;	1984
[The amiodarone lung]. Revue de pneumologie clinique, 1984, Volume: 40, Issue:1 Topics: Amiodarone; Benzofurans; Humans; Lung; Lung Diseases; Time Factors	1984
Amiodarone: the experience of the past decade. British medical journal (Clinical research ed.), 1983, Dec-03, Volume: 287, Issue:6406 Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Dose-Response Relationship, Drug; Drug Interactions;	1983
Drug-induced pulmonary disease. Seminars in respiratory infections, 1995, Volume: 10, Issue:2 Topics: Amiodarone; Bleomycin; Busulfan; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Humans; Immu	1995
[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids]. Archivos de bronconeumologia, 1995, Volume: 31, Issue:8 Topics: Amiodarone; Dose-Response Relationship, Drug; Humans; Lung Diseases; Male; Methylprednisolone; Middl	1995
[Drug-induced lung diseases]. La Clinica terapeutica, 1994, Volume: 145, Issue:7 Topics: Adult; Aged; Amiodarone; Animals; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Ch	1994
Amiodarone pulmonary toxicity: a multidisciplinary review of current status. Southern medical journal, 1993, Volume: 86, Issue:1 Topics: Amiodarone; Bronchoalveolar Lavage Fluid; Humans; Lung; Lung Diseases; Macrophages, Alveolar; Progno	1993
[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?]. Ugeskrift for laeger, 1996, Jun-10, Volume: 158, Issue:24 Topics: Amiodarone; Anti-Arrhythmia Agents; Evaluation Studies as Topic; Humans; Lung; Lung Diseases; Lung V	1996
[Physiopathologic mechanisms of drug-induced lung diseases in man]. Revue des maladies respiratoires, 1996, Volume: 13, Issue:2 Topics: Adjuvants, Immunologic; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antibiotics, Anti	1996
Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Canadian journal of physiology and pharmacology, 1995, Volume: 73, Issue:12 Topics: Amiodarone; Animals; Disease Models, Animal; Humans; Lung; Lung Diseases	1995
[Amiodarone and the lung]. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 1996, Volume: 15, Issue:10 Topics: Amiodarone; Anti-Arrhythmia Agents; Bronchoscopy; Humans; Lung Diseases; Risk Factors	1996
Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Drug safety, 1998, Volume: 18, Issue:5 Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Lung Diseases; Risk Factors; Vasodilator Agents	1998
Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. The American journal of cardiology, 1999, Nov-04, Volume: 84, Issue:9A Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Corneal Opacity; Diagnosis, Differential; Humans; Lung	1999
[Drug induced pulmonary symptoms in medicine]. Duodecim; laaketieteellinen aikakauskirja, 1996, Volume: 112, Issue:19 Topics: Amiodarone; Amphotericin B; Bronchoconstriction; Drug-Related Side Effects and Adverse Reactions; Fe	1996
[Amiodarone pulmonary toxicity]. Recenti progressi in medicina, 1999, Volume: 90, Issue:12 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Lung Diseases	1999
[Pulmonary toxicity caused by drugs]. Archivos de bronconeumologia, 1999, Volume: 35, Issue:11 Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents, Urinary; Anti-Inflammatory	1999
Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. The Canadian journal of cardiology, 2000, Volume: 16, Issue:11 Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Lung; Lung Diseases; Radiography; Risk Factors	2000
Intravenous amiodarone in intensive care. Time for a reappraisal? Intensive care medicine, 2000, Volume: 26, Issue:12 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Critical Care; Critical Illness; Drug Inte	2000
Drug-induced pulmonary disease. The Medical journal of Australia, 1992, Jun-01, Volume: 156, Issue:11 Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aerosols; Amiodarone; Angioten	1992
The histopathology of pulmonary reactions to drugs. Clinics in chest medicine, 1990, Volume: 11, Issue:1 Topics: Amiodarone; Antirheumatic Agents; Biopsy; Bleomycin; Cyclophosphamide; Diagnosis, Differential; Eosi	1990
Pulmonary toxicity induced by chemical agents. The European respiratory journal, 1990, Volume: 3, Issue:3 Topics: Amiodarone; Animals; Asbestos; Bleomycin; Bronchoalveolar Lavage Fluid; Cyclophosphamide; Gold; Huma	1990
The role of chest computed tomography in the diagnosis of drug-related reactions. Journal of thoracic imaging, 1991, Volume: 6, Issue:1 Topics: Amiodarone; Bleomycin; Drug Hypersensitivity; Humans; Immunoblastic Lymphadenopathy; Lung; Lung Dise	1991
[Does amiodarone have a benefit effect on mortality?]. Presse medicale (Paris, France : 1983), 1991, Sep-14, Volume: 20, Issue:28 Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Eye Diseases; France; Heart Arrest; Humans	1991
Clinical aspects of amiodarone pulmonary toxicity. Clinics in chest medicine, 1990, Volume: 11, Issue:1 Topics: Amiodarone; Bronchoalveolar Lavage Fluid; Dyspnea; Humans; Lung Diseases; Prognosis	1990
Mechanisms of amiodarone pulmonary toxicity. Clinics in chest medicine, 1990, Volume: 11, Issue:1 Topics: Amiodarone; Humans; Lung; Lung Diseases; Phospholipids	1990
Drug-induced adverse pulmonary reactions. Adverse drug reactions and acute poisoning reviews, 1985,Winter, Volume: 4, Issue:4 Topics: Amiodarone; Asthma; Bleomycin; Carmustine; Drug-Related Side Effects and Adverse Reactions; Gold; Hu	1985
Mechanisms of drug-induced pulmonary disease. Annual review of medicine, 1988, Volume: 39 Topics: Alveolitis, Extrinsic Allergic; Amiodarone; Bleomycin; Bronchial Spasm; Humans; Lung Diseases; Pulmo	1988
[Amiodarone and its side effects]. Nederlands tijdschrift voor geneeskunde, 1988, Mar-26, Volume: 132, Issue:13 Topics: Amiodarone; Chemical and Drug Induced Liver Injury; Corneal Diseases; Humans; Lung Diseases; Periphe	1988
[Collateral effects of an anti-arrhythmic agent: amiodarone]. La Clinica terapeutica, 1985, Sep-30, Volume: 114, Issue:6 Topics: Amiodarone; Benzofurans; Chemical and Drug Induced Liver Injury; Eye Diseases; Humans; Hyperthyroidi	1985
[Side effects of amiodarone on the lungs]. Klinicheskaia meditsina, 1988, Volume: 66, Issue:8 Topics: Amiodarone; Dose-Response Relationship, Drug; Humans; Lung; Lung Diseases; Prognosis; Radiography; R	1988
Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest, 1988, Volume: 93, Issue:5 Topics: Amiodarone; Bronchoscopy; Diagnostic Imaging; Humans; Lung; Lung Diseases; Respiratory Function Test	1988
Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest, 1988, Volume: 93, Issue:6 Topics: Amiodarone; Bronchoalveolar Lavage Fluid; Humans; Lung Diseases; Lymphocytes	1988
[Pulmonary toxicity caused by amiodarone]. Medicina clinica, 1986, Jul-12, Volume: 87, Issue:6 Topics: Amiodarone; Benzofurans; Dose-Response Relationship, Drug; Drug Hypersensitivity; Humans; Lung Disea	1986
Clinical use of amiodarone. Heart & lung : the journal of critical care, 1985, Volume: 14, Issue:4 Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Corneal Diseases; Electrophysiology; Heart; Humans; H	1985

Article	Year
Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance. International journal of cardiology, 2009, May-15, Volume: 134, Issue:2 Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Flow Cytometry; Human	2009
A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. The Annals of thoracic surgery, 2009, Volume: 88, Issue:3 Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Non-	2009
Technetium-99m-DTPA aerosol scintigraphy in amiodarone induced pulmonary toxicity in comparison with Ga-67 scintigraphy. Annals of nuclear medicine, 2002, Volume: 16, Issue:7 Topics: Administration, Inhalation; Aerosols; Aged; Amiodarone; Citrates; Female; Gallium; Humans; Lung; Lun	2002
Detection of amiodarone-induced pulmonary toxicity in supine and prone positions: high-resolution computed tomography study. Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:4 Topics: Adult; Aged; Amiodarone; Antigens; Antigens, Neoplasm; Diagnosis, Differential; False Positive React	2005
Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibril	2008
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (the CASCADE study). The American journal of cardiology, 1991, Mar-15, Volume: 67, Issue:7 Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Female; Heart Arrest; Humans; L	1991
Work of cardiology community results in approval of amiodarone. FDA drug bulletin, 1986, Volume: 16, Issue:1 Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Clinical Trials as Topic; Humans; Lung Diseases; Unit	1986
[Extracardiac side effects of Aminodarone]. Giornale italiano di cardiologia, 1986, Volume: 16, Issue:2 Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Clinical Trials as Topic; Drug Evaluation; Eye Diseas	1986